HK1232214A1 - 作為 抑制劑的六氫呋喃並吡咯 - Google Patents

作為 抑制劑的六氫呋喃並吡咯

Info

Publication number
HK1232214A1
HK1232214A1 HK17105707.4A HK17105707A HK1232214A1 HK 1232214 A1 HK1232214 A1 HK 1232214A1 HK 17105707 A HK17105707 A HK 17105707A HK 1232214 A1 HK1232214 A1 HK 1232214A1
Authority
HK
Hong Kong
Prior art keywords
pde1
hexahydrofuropyrroles
inhibitors
pde1 inhibitors
inhibitors pde1
Prior art date
Application number
HK17105707.4A
Other languages
English (en)
Inventor
．科勒
．拉斯馬森
．朗戈爾德
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58698416&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1232214(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of HK1232214A1 publication Critical patent/HK1232214A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
HK17105707.4A 2014-02-07 2017-06-09 作為 抑制劑的六氫呋喃並吡咯 HK1232214A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA201400069 2014-02-07
PCT/EP2015/052492 WO2015118097A1 (en) 2014-02-07 2015-02-06 Hexahydrofuropyrroles as pde1 inhibitors

Publications (1)

Publication Number Publication Date
HK1232214A1 true HK1232214A1 (zh) 2018-01-05

Family

ID=58698416

Family Applications (1)

Application Number Title Priority Date Filing Date
HK17105707.4A HK1232214A1 (zh) 2014-02-07 2017-06-09 作為 抑制劑的六氫呋喃並吡咯

Country Status (26)

Country Link
US (1) US9718832B2 (zh)
EP (1) EP3102584B1 (zh)
JP (1) JP6532880B2 (zh)
KR (1) KR20160115931A (zh)
CN (1) CN106414459B (zh)
AP (1) AP2016009344A0 (zh)
AR (1) AR099300A1 (zh)
AU (1) AU2015214214A1 (zh)
CA (1) CA2935470A1 (zh)
CL (1) CL2016001959A1 (zh)
CR (1) CR20160322A (zh)
DO (1) DOP2016000179A (zh)
EA (1) EA201691335A1 (zh)
EC (1) ECSP16071574A (zh)
ES (1) ES2711085T3 (zh)
GE (1) GEP201706795B (zh)
HK (1) HK1232214A1 (zh)
IL (1) IL246718A0 (zh)
MA (1) MA39230B1 (zh)
MX (1) MX2016010168A (zh)
PE (1) PE20161071A1 (zh)
PH (1) PH12016501495A1 (zh)
RU (1) RU2016130684A (zh)
SG (1) SG11201606445YA (zh)
TW (1) TW201611834A (zh)
WO (1) WO2015118097A1 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2943011A1 (en) * 2014-04-04 2015-10-08 H. Lundbeck A/S Halogenated quinazolin-thf-amines as pde1 inhibitors
MX2019007803A (es) 2016-12-28 2019-08-29 Dart Neuroscience Llc Compuestos de pirazolopirimidinona sustituida como inhibidores de fosfodiesterasas 2 (pde2).
KR20200108419A (ko) 2017-11-27 2020-09-18 다트 뉴로사이언스, 엘엘씨 Pde1 억제제로서의 치환된 푸라노피리미딘 화합물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060183763A1 (en) * 2004-12-31 2006-08-17 Pfizer Inc Novel pyrrolidyl derivatives of heteroaromatic compounds
EP2057153B1 (en) * 2006-07-10 2012-09-12 H. Lundbeck A/S (3-aryl-piperazin-1-yl) derivatives of 6,7-dialkoxyquinazoline, 6,7- dialkoxyphtalazine and 6,7-dialkoxyisoquinoline
EP2231558B1 (en) * 2007-12-14 2014-09-03 Merck Sharp & Dohme Corp. 3,4-substituted pyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease

Also Published As

Publication number Publication date
JP2017505328A (ja) 2017-02-16
MA39230B1 (fr) 2018-04-30
CN106414459B (zh) 2018-08-03
GEP201706795B (en) 2017-12-11
WO2015118097A1 (en) 2015-08-13
AR099300A1 (es) 2016-07-13
ES2711085T3 (es) 2019-04-30
KR20160115931A (ko) 2016-10-06
DOP2016000179A (es) 2016-09-30
ECSP16071574A (es) 2017-02-24
PH12016501495A1 (en) 2017-02-06
SG11201606445YA (en) 2016-09-29
IL246718A0 (en) 2016-08-31
CN106414459A (zh) 2017-02-15
MX2016010168A (es) 2016-10-07
MA39230A1 (fr) 2017-07-31
US9718832B2 (en) 2017-08-01
EP3102584B1 (en) 2019-01-16
CL2016001959A1 (es) 2017-02-24
EP3102584A1 (en) 2016-12-14
TW201611834A (en) 2016-04-01
RU2016130684A (ru) 2018-03-15
AP2016009344A0 (en) 2016-07-31
CR20160322A (es) 2016-09-16
PE20161071A1 (es) 2016-10-30
AU2015214214A1 (en) 2016-07-14
CA2935470A1 (en) 2015-08-13
EA201691335A1 (ru) 2016-12-30
JP6532880B2 (ja) 2019-06-19
US20160347759A1 (en) 2016-12-01

Similar Documents

Publication Publication Date Title
IL287113A (en) smyd inhibitors
IL251420A0 (en) Triazolopyrazinones as pde1 inhibitors
HK1249097A1 (zh) 作為pde1抑制劑的咪唑並三嗪酮
IL246785A0 (en) Benzimidazole-2-amines as midh1 inhibitors
HK1226398A1 (zh) 作為midh1抑制劑的苯並咪唑-2-胺
IL248895A0 (en) Phosphatidylinositol 3-kinase inhibitors
HK1252098B (zh) 作為pde1抑制劑的咪唑並吡嗪酮
GB201501004D0 (en) Inhibitors
IL252866B (en) History of imidazopyridazine as pi3k beta inhibitors
HK1232214A1 (zh) 作為 抑制劑的六氫呋喃並吡咯
IL248078B (en) Halogenated thf quinazoline amines as pde1 inhibitors
GB201401005D0 (en) Inhibitor
GB201520949D0 (en) Inhibitors
GB201418154D0 (en) Inhibitors